Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphomaPrakash Satwani, Mitchell S. Cairo, Zhezhen Jin et al.|Leukemia|2014Cited by 53
A novel trial of topotecan, ifosfamide, and carboplatin (TIC) in children with recurrent solid tumorsKavita Radhakrishnan, Mitchell S. Cairo, Robert J. Wells et al.|Pediatric Blood & Cancer|2014Cited by 2
Sequential Myeloablative Autologous Stem Cell Transplantation and Reduced Intensity Allogeneic Stem Cell Transplantation in Children, Adolescents and Young Adults with Poor Risk Refractory or Recurrent Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL)Prakash Satwani, Mitchell S. Cairo, Joanne Kurtzberg et al.|Transplantation and Cellular Therapy|2014Cited by 1